Suppr超能文献

脂蛋白(a)、心血管事件与性别差异:单一心脏病科的经验

Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience.

作者信息

Pino Beatrice Dal, Gorini Francesca, Gaggini Melania, Landi Patrizia, Pingitore Alessandro, Vassalle Cristina

机构信息

Fondazione Gabriele Monasterio CNR-Regione Toscana, 56124 Pisa, Italy.

Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.

出版信息

J Clin Med. 2023 Jan 18;12(3):764. doi: 10.3390/jcm12030764.

Abstract

Lipoprotein(a)-Lp(a), which retains proatherogenic and prothrombotic properties, may be modified by hormonal and metabolic factors. However, few studies have focused on differences related to sex and cardiometabolic risk factors in the relationship between Lp(a) and cardiovascular disease, especially in terms of prognosis. This study aimed at evaluating the predictive value of Lp(a) (cut-off 30 mg/dL) for hard events (HEs: mortality and non-fatal myocardial infarction) according to sex and cardiometabolic risk factors in 2110 patients (1501 males, mean age: 68 ± 9 years) undergoing coronary angiography for known or suspected coronary artery disease. There were 211 events over a median follow-up period of 33 months. Lp(a) > 30 mg/dL did not confer a worse prognosis on the overall population. However, Kaplan-Meier subgroup analysis evidenced a worse prognosis in type 2 diabetes (T2D) females with elevated Lp(a) (log-rank test: = 0.03) vs. T2D males and no-T2D patients, but not in other high-risk cardiovascular states (e.g., smoking, hypertension, reduced left ventricular ejection fraction or obesity). After Cox multivariate adjustment, Lp(a) remained an independent determinant for HEs in the T2D female subgroup, conferring an HR of 2.9 (95% CI 1.1-7.7, < 0.05). Lp(a) is therefore a strong independent predictor of HR in T2D women, but not in T2D men, or in noT2D patients.

摘要

脂蛋白(a)-Lp(a)具有促动脉粥样硬化和促血栓形成特性,可能会受到激素和代谢因素的影响。然而,很少有研究关注Lp(a)与心血管疾病关系中与性别和心血管代谢危险因素相关的差异,尤其是在预后方面。本研究旨在评估Lp(a)(临界值30 mg/dL)对2110例(1501例男性,平均年龄:68±9岁)因已知或疑似冠状动脉疾病接受冠状动脉造影的患者发生硬性事件(HEs:死亡和非致命性心肌梗死)的预测价值。在中位随访期33个月内共发生211起事件。Lp(a)>30 mg/dL对总体人群并未带来更差的预后。然而,Kaplan-Meier亚组分析表明,Lp(a)升高的2型糖尿病(T2D)女性与T2D男性和非T2D患者相比预后更差(对数秩检验:=0.03),但在其他高危心血管状态(如吸烟、高血压、左心室射血分数降低或肥胖)中并非如此。经过Cox多变量调整后,Lp(a)仍然是T2D女性亚组中硬性事件的独立决定因素,风险比为2.9(95%可信区间1.1-7.7,<0.05)。因此,Lp(a)是T2D女性发生硬性事件的强有力独立预测因素,但在T2D男性或非T2D患者中并非如此。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4e/9918149/14d422c867ae/jcm-12-00764-g001.jpg

相似文献

2
Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients.
Int J Cardiol. 2013 Sep 1;167(5):1990-4. doi: 10.1016/j.ijcard.2012.05.007. Epub 2012 May 24.
4
Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes.
Eur J Clin Invest. 2019 Jul;49(7):e13117. doi: 10.1111/eci.13117. Epub 2019 May 7.
6
Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease.
Heart. 2020 Aug;106(16):1228-1235. doi: 10.1136/heartjnl-2020-316586. Epub 2020 May 7.
7
Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit.
Heart Lung Circ. 2021 May;30(5):734-740. doi: 10.1016/j.hlc.2020.09.932. Epub 2020 Nov 12.
8
Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.
Atherosclerosis. 2022 Dec;363:109-116. doi: 10.1016/j.atherosclerosis.2022.10.013. Epub 2022 Oct 25.
9
High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarction Patients.
Vasc Health Risk Manag. 2020 Apr 8;16:125-132. doi: 10.2147/VHRM.S233503. eCollection 2020.

引用本文的文献

1
Lipoprotein(a) and panvascular disease.
Lipids Health Dis. 2025 May 24;24(1):186. doi: 10.1186/s12944-025-02600-y.
3
Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review.
Pharmaceuticals (Basel). 2024 Jul 9;17(7):913. doi: 10.3390/ph17070913.

本文引用的文献

1
Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.
Atherosclerosis. 2022 Dec;363:109-116. doi: 10.1016/j.atherosclerosis.2022.10.013. Epub 2022 Oct 25.
2
Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis. 2022 Dec;363:102-108. doi: 10.1016/j.atherosclerosis.2022.10.004. Epub 2022 Oct 8.
3
Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis.
Eur J Clin Invest. 2022 Nov;52(11):e13855. doi: 10.1111/eci.13855. Epub 2022 Sep 7.
4
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias.
J Clin Med. 2022 Jul 4;11(13):3884. doi: 10.3390/jcm11133884.
5
Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Different Metabolic Phenotypes.
Front Cardiovasc Med. 2022 May 20;9:870341. doi: 10.3389/fcvm.2022.870341. eCollection 2022.
7
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective.
Atherosclerosis. 2022 May;349:7-16. doi: 10.1016/j.atherosclerosis.2022.04.015.
8
Lipoprotein (a) and diabetes mellitus.
Atherosclerosis. 2022 May;349:63-71. doi: 10.1016/j.atherosclerosis.2022.04.016.
9
Non-genetic influences on lipoprotein(a) concentrations.
Atherosclerosis. 2022 May;349:53-62. doi: 10.1016/j.atherosclerosis.2022.04.006.
10
Existing and emerging strategies to lower Lipoprotein(a).
Atherosclerosis. 2022 May;349:110-122. doi: 10.1016/j.atherosclerosis.2022.04.020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验